217 related articles for article (PubMed ID: 20643906)
1. Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas.
Van Goietsenoven G; Hutton J; Becker JP; Lallemand B; Robert F; Lefranc F; Pirker C; Vandenbussche G; Van Antwerpen P; Evidente A; Berger W; Prévost M; Pelletier J; Kiss R; Kinzy TG; Kornienko A; Mathieu V
FASEB J; 2010 Nov; 24(11):4575-84. PubMed ID: 20643906
[TBL] [Abstract][Full Text] [Related]
2. Narciclasine as well as other Amaryllidaceae isocarbostyrils are promising GTP-ase targeting agents against brain cancers.
Van Goietsenoven G; Mathieu V; Lefranc F; Kornienko A; Evidente A; Kiss R
Med Res Rev; 2013 Mar; 33(2):439-55. PubMed ID: 22419031
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents.
Ingrassia L; Lefranc F; Dewelle J; Pottier L; Mathieu V; Spiegl-Kreinecker S; Sauvage S; El Yazidi M; Dehoux M; Berger W; Van Quaquebeke E; Kiss R
J Med Chem; 2009 Feb; 52(4):1100-14. PubMed ID: 19199649
[TBL] [Abstract][Full Text] [Related]
4. Narciclasine, an isocarbostyril alkaloid, has preferential activity against primary effusion lymphoma.
Gopalakrishnan R; Matta H; Choi S; Chaudhary PM
Sci Rep; 2020 Mar; 10(1):5712. PubMed ID: 32235878
[TBL] [Abstract][Full Text] [Related]
5. Narciclasine - an Amaryllidaceae Alkaloid with Potent Antitumor and Anti-Inflammatory Properties.
Fürst R
Planta Med; 2016 Nov; 82(16):1389-1394. PubMed ID: 27542176
[TBL] [Abstract][Full Text] [Related]
6. Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells.
Lefranc F; Sauvage S; Van Goietsenoven G; Mégalizzi V; Lamoral-Theys D; Debeir O; Spiegl-Kreinecker S; Berger W; Mathieu V; Decaestecker C; Kiss R
Mol Cancer Ther; 2009 Jul; 8(7):1739-50. PubMed ID: 19531573
[TBL] [Abstract][Full Text] [Related]
7. The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts.
Dumont P; Ingrassia L; Rouzeau S; Ribaucour F; Thomas S; Roland I; Darro F; Lefranc F; Kiss R
Neoplasia; 2007 Sep; 9(9):766-76. PubMed ID: 17898872
[TBL] [Abstract][Full Text] [Related]
8. Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight.
Lamoral-Theys D; Andolfi A; Van Goietsenoven G; Cimmino A; Le Calvé B; Wauthoz N; Mégalizzi V; Gras T; Bruyère C; Dubois J; Mathieu V; Kornienko A; Kiss R; Evidente A
J Med Chem; 2009 Oct; 52(20):6244-56. PubMed ID: 19788245
[TBL] [Abstract][Full Text] [Related]
9. C1,C2-ether derivatives of the Amaryllidaceae alkaloid lycorine: retention of activity of highly lipophilic analogues against cancer cells.
Dasari R; Banuls LM; Masi M; Pelly SC; Mathieu V; Green IR; van Otterlo WA; Evidente A; Kiss R; Kornienko A
Bioorg Med Chem Lett; 2014 Feb; 24(3):923-7. PubMed ID: 24393582
[TBL] [Abstract][Full Text] [Related]
10. Haemanthus coccineus extract and its main bioactive component narciclasine display profound anti-inflammatory activities in vitro and in vivo.
Fuchs S; Hsieh LT; Saarberg W; Erdelmeier CA; Wichelhaus TA; Schaefer L; Koch E; Fürst R
J Cell Mol Med; 2015 May; 19(5):1021-32. PubMed ID: 25754537
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of unnatural derivatives of narciclasine: 7-aza-nornarciclasine and its N-oxide.
Vshyvenko S; Reisenauer MR; Rogelj S; Hudlicky T
Bioorg Med Chem Lett; 2014 Sep; 24(17):4236-8. PubMed ID: 25108300
[TBL] [Abstract][Full Text] [Related]
12. Narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis.
Cao C; Huang W; Zhang N; Wu F; Xu T; Pan X; Peng C; Han B
Cell Prolif; 2018 Dec; 51(6):e12518. PubMed ID: 30152053
[TBL] [Abstract][Full Text] [Related]
13. Biological evaluation of ent-narciclasine, ent-lycoricidine, and certain enantiomerically-related congeners.
Matveenko M; Banwell MG; Joffe M; Wan S; Fantino E
Chem Biodivers; 2009 May; 6(5):685-91. PubMed ID: 19479847
[TBL] [Abstract][Full Text] [Related]
14. Narciclasine-4-
Katoch D; Kumar D; Padwad YS; Singh B; Sharma U
Nat Prod Res; 2020 Jan; 34(2):233-240. PubMed ID: 30636443
[TBL] [Abstract][Full Text] [Related]
15. Amaryllidaceae alkaloids belonging to different structural subgroups display activity against apoptosis-resistant cancer cells.
Van Goietsenoven G; Andolfi A; Lallemand B; Cimmino A; Lamoral-Theys D; Gras T; Abou-Donia A; Dubois J; Lefranc F; Mathieu V; Kornienko A; Kiss R; Evidente A
J Nat Prod; 2010 Jul; 73(7):1223-7. PubMed ID: 20550100
[TBL] [Abstract][Full Text] [Related]
16. Antineoplastic agents. 527. Synthesis of 7-deoxynarcistatin, 7-deoxy-trans-dihydronarcistatin, and trans-dihydronarcistatin 1(1).
Pettit GR; Melody N
J Nat Prod; 2005 Feb; 68(2):207-11. PubMed ID: 15730244
[TBL] [Abstract][Full Text] [Related]
17. Biological evaluation of structurally diverse amaryllidaceae alkaloids and their synthetic derivatives: discovery of novel leads for anticancer drug design.
Evidente A; Kireev AS; Jenkins AR; Romero AE; Steelant WF; Van Slambrouck S; Kornienko A
Planta Med; 2009 Apr; 75(5):501-7. PubMed ID: 19235683
[TBL] [Abstract][Full Text] [Related]
18. The Amaryllidaceae Alkaloid Haemanthamine Binds the Eukaryotic Ribosome to Repress Cancer Cell Growth.
Pellegrino S; Meyer M; Zorbas C; Bouchta SA; Saraf K; Pelly SC; Yusupova G; Evidente A; Mathieu V; Kornienko A; Lafontaine DLJ; Yusupov M
Structure; 2018 Mar; 26(3):416-425.e4. PubMed ID: 29429877
[TBL] [Abstract][Full Text] [Related]
19. Yeast translation elongation factor-1A binds vacuole-localized Rho1p to facilitate membrane integrity through F-actin remodeling.
Bodman JAR; Yang Y; Logan MR; Eitzen G
J Biol Chem; 2015 Feb; 290(8):4705-4716. PubMed ID: 25561732
[TBL] [Abstract][Full Text] [Related]
20. Narciclasine inhibits angiogenic processes by activation of Rho kinase and by downregulation of the VEGF receptor 2.
Bräutigam J; Bischoff I; Schürmann C; Buchmann G; Epah J; Fuchs S; Heiss E; Brandes RP; Fürst R
J Mol Cell Cardiol; 2019 Oct; 135():97-108. PubMed ID: 31381906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
